ClinicalTrials.gov
public full text
Public Domain
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
The main objectives of the project are: * To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI) * To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of Omalizumab in the Skin of Food Allergy Patients#905841
- Topical CP-690,550 For Chronic Plaque Psoriasis#825385
- Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis#846706
- MIcrovascular dysfuNction In Moderate-severe Psoriasis#829316
- Treatment Goals in Psoriatic Arthritis#805507
Record · ID 1379033
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive